This time the US Food and Drug Administration has approved a drug meant for treating chronic myelogenous leukemia or CML, a report has unveiled newly.

The certification, though only for use by older adults, is being seen after the success of a trial for the drug that showed other drugs were benefitting less than Bosulif. While imanitib-treated patients experienced a major cytogenetic response (MCyR) after first 24 weeks, it was noted that those who had received imatinib followed by nilotinib or dasatinib, reached the same within 24 weeks.

The other three drugs have already been approved by the drug agency to treat other forms of CML. 546 adult patients with blast phase CML were tested in the trial, who had failed to respond to these. Also, it is thus that Bosulif's efficacy was checked with the amount of patients' experience of MCyR.

In the meanwhile, the report finds that CML is a condition, whose patients have a genetic mutation Philadelphia chromosome. The mutation occurs where tyrosine kinase, an enzyme is produced by the bone marrow to create as many unhealthy white blood cells. The cells dubbed granulocytes help fight infection.

It is being feared that 5,430 people may suffer the same this year. But, at the same time, the drug is a great hope to fight it.